Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as procarbazine hydrochloride
procarbazine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| leflunomide | DRUG | - |
| procarbazine hydrochloride | DRUG | - |
DISEASE CHARACTERISTICS: Histologically proven refractory or recurrent supratentorial glioblastoma multiforme Bidimensionally measurable, enhancing residual disease by T1-weighted gadolinium-enhanced MRI required within 15 days prior to treatment Stable dose of corticosteroids required for at least ...
Procarbazine is used in the treatment of brain and central nervous system tumors, including glioblastoma multiforme. It is an oncology small molecule that has been studied in a Phase 3 trial comparing it with another agent in patients with glioblastoma multiforme. It is also known as procarbazine hydrochloride.
Procarbazine is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. Pfizer is the company associated with the clinical development of procarbazine for brain and central nervous system tumors.
Procarbazine has been evaluated in a Phase 3 clinical trial. The trial, NCT00003293, is completed. There are no active trials of procarbazine listed. The drug is investigational in this development program and is not described as approved.
Procarbazine was studied in one Phase 3 clinical trial, NCT00003293, titled SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme. The trial was completed, was randomized, and enrolled patients in the United States and Canada. It included adults 18 years and older of all sexes.
Yes, procarbazine is also known as procarbazine hydrochloride. The two names refer to the same drug. Procarbazine hydrochloride is the alternative name used for this oncology small molecule developed by Pfizer for brain and central nervous system tumors.